Ultime notizie per Plus Therapeutics (NASDAQ:PSTV) Azioni

Plus Therapeutics

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Plus Therapeutics Inc

POSTAL SVGS CHINA UNS/ADR by Postal Svgs Bk of China Ltd.

Postal Savings Bank Of China Co Ltd

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is <a href="https://www.benzinga.com/quote/VRTX/earnings">entering earnings week</a> with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 12 months. But with a 3.5% pullback in the past month, all eyes are now on its first-quarter report, expected to drop shortly on May 5, after market hours.
<h1 class="wp-block-heading">Alyftrek and Journavx — The Two Big Launches</h1>
According to JPMorgan analyst Jessica Fye, investors will be laser-focused on the company&#8217;s two big launches: Alyftrek and Journavx. While Vertex's cystic fibrosis heavyweight Trikafta is still expected to bring in the bulk of first quarter revenue — $2.51 billion of the $2.74 billion total JPMorgan is modeling — international headwinds, particularly from Russia's disregard of IP rights, could muddy the picture.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/04/44670084/vertexs-journavx-launch-sparks-optimism-analyst-sees-two-potential-upside-levers">Vertex&#8217;s Journavx Launch Sparks Optimism, Analyst Sees &#8216;Two Potential Upside Levers&#8217;</a>
The wildcards? Alyftrek and Journavx. JPMorgan pegs Alyftrek at $50 million in sales and Journavx at less than $1 million, but says upside surprises could emerge if there's more channel stocking or better-than-expected uptake. IQVIA script trends for Journavx, while early, have already outpaced what Fye calls "low investor expectations." 
What remains to be seen is where the uptake is coming from — retail or hospitals — and how insurance coverage and patient types shake out.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21133056/Screenshot-2025-04-21-at-11.00.43-PM.png" alt="" class="wp-image-880332" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21133056/Screenshot-2025-04-21-at-11.00.43-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/21133056/Screenshot-2025-04-21-at-11.00.43-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0421" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
On the charts, Vertex stock is technically leaning bullish. It&#8217;s trading above its 20-day, 50-day and 200-day simple moving averages, although just barely below its eight-day SMA. The Moving Average Convergence Divergence (MACD) and slight buying pressure suggest cautious optimism, despite the stock's recent cool-down.
Bottom line? 
With multiple pipeline catalysts and the first quarter potentially validating new product momentum, Vertex could quickly recapture investor enthusiasm — or leave analysts recalibrating expectations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">Trump&#8217;s New Order Targets Drug Pricing Transparency And Medicare Cost Reduction</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Long Ideas

Health Care

Technicals

Analyst Ratings

Trading Ideas

General

VRTX

Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely

Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are trading lower on Monday after Huawei announced it&#8217;s preparing a new artificial intelligence (AI) chip as an alternative <a href="https://www.benzinga.com/25/04/44897966/huawei-prepares-for-bulk-shipment-of-new-advanced-ai-chip-as-china-seeks-nvidia-alternatives">to Nvidia&#8217;s H20 line</a>.
The Details: Huawei plans to begin shipping its advanced 910C AI chip to customers in China as soon as next month, according to Reuters. The chip achieves performance on par with Nvidia's H100 chip by using two 910B processors combined into a single unit through advanced integration methods.
Last week, President Donald Trump's administration <a href="https://www.benzinga.com/news/global/25/04/44828742/nvidia-stock-is-tumbling-after-hours-heres-why">introduced licensing requirements</a> for the sale of Nvidia&#8217;s H20 chips to China. A license will also be required for any chips that match the H20's memory bandwidth, interconnect bandwidth or a combination of both.
Nvidia shares may be lower as investors assess the competitive threat posed by Huawei and its novel chip. The recent export restrictions on Nvidia's H20 chips may also be fueling concerns about the company's ability to maintain its foothold in the Chinese market.
What Else: Deteriorating U.S.-China trade relations continue to weigh on the stock as well. For instance, the Trump administration has imposed a <a href="https://www.benzinga.com/25/04/44888445/ford-reportedly-halts-vehicle-shipments-to-china-amid-rising-tariffs">wide range of tariffs</a> on China. In response, China has filed a complaint with the World Trade Organization.
Trump has now raised concerns about escalating tariffs, warning that they could further strain U.S.-China trade relations.
Such tensions add uncertainty for companies like Nvidia that rely on the Chinese market, where higher tariffs and regulatory hurdles could hurt sales and long-term growth.
Related Link: <a href="https://www.benzinga.com/markets/emerging-markets/25/04/44904375/tesla-rival-byd-targets-japans-minicar-market-with-for-new-affordable-ev">Tesla Rival BYD Targets Japan&#8217;s Minicar Market With For New Affordable EV</a>
NVDA Price Action: At the time of writing, Nvidia stock is trading 6.30% lower at $95.10, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

News

Movers

NVDA

What's Going On With Nvidia Stock Monday?

DA Davidson analyst Peter Winter maintains Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) with a Neutral and lowers the price target from $45 to $42.

Price Target

FITB

DA Davidson Maintains Neutral on Fifth Third Bancorp, Lowers Price Target to $42

Wolfe Research analyst Andrew Rosivach downgrades Prologis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades Prologis to Peer Perform

Wolfe Research analyst Andy Chen upgrades Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) from Peer Perform to Outperform and announces $21 price target.

Upgrades

NTLA

Wolfe Research Upgrades Intellia Therapeutics to Outperform, Announces $21 Price Target

Northland Capital Markets analyst Mike Grondahl initiates coverage on Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Outperform rating and announces Price Target of $20.

Initiation

Northland Capital Markets Initiates Coverage On Hut 8 with Outperform Rating, Announces Price Target of $20

Wolfe Research analyst Devin Brisco upgrades Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) from Peer Perform to Outperform and announces $660 price target.

SPOT

Wolfe Research Upgrades Spotify Technology to Outperform, Announces $660 Price Target

Klaus Schwab, Founder and Chairman of the World Economic Forum&#8217;s (WEF) Board of Trustees, has officially resigned after 55 years of service in the Geneva-based institution.
Schwab, who is entering his 88th year, informed the Board of Trustees of his decision, effective immediately.
&#8220;Following my recent announcement, and as I enter my 88th year, I have decided to step down from the position of Chair and as a member of the Board of Trustees, with immediate effect,&#8221; Schwab stated in an official release from the Forum.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline</a>
At an extraordinary meeting on 20 April, the Board of Trustees <a target="_blank" href="https://www.weforum.org/press/2025/04/world-economic-forum-announces-governance-transition/" rel="noreferrer noopener">noted</a> Klaus Schwab&#8217;s resignation. In accordance with the Forum&#8217;s Rules and Regulations, the Board unanimously appointed Vice Chairman Peter Brabeck-Letmathe as Chairman ad interim. It also established a Search Committee to select a future Chair.
&#8220;At a time when the world is undergoing rapid transformation, the need for inclusive dialogue to navigate complexity and shape the future has never been more critical. The Board of Trustees of the World Economic Forum underlines the importance of remaining steadfast in its mission and values as a facilitator of progress,&#8221; the institution said in a press release on Monday.
In January, the World Economic Forum <a target="_blank" href="https://www.novartis.com/events/world-economic-forum-annual-meeting-2025" rel="noreferrer noopener">held</a> its Annual Meeting in Davos-Klosters. The event brought together over 350 government leaders, including 60 heads of state and government.
U.S. President Donald Trump made a&nbsp;special address&nbsp;at Davos just three days after being inaugurated as the 47th president.
Trump <a target="_blank" href="https://www.weforum.org/stories/2025/01/davos-2025-special-address-donald-trump-president-united-states/" rel="noreferrer noopener">said</a> his administration is working to fix the &#8216;economic chaos&#8217; and will make the U.S. &#8216;stronger, wealthier and more united than ever before&#8217;.
He added that he would work to bring down oil and gas prices, eliminate regulations, introduce tax cuts for domestic producers, and impose tariffs on foreign goods.
The Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/davos-founder-klaus-schwab-to-step-aside-as-forums-chair-0f3231b0" rel="noreferrer noopener">reports</a> that the World Economic Forum has been making leadership changes recently after the Board reviewed the results of a workplace culture investigation.
The probe followed a Journal article last year in which employees accused the organization of discriminating against women and Black people.
The Forum denied the report, and founder Klaus Schwab rejected the claims against him.
In a recent memo, CEO Børge Brende said the investigation didn&#8217;t confirm the allegations against Schwab but did highlight leadership issues that the Forum plans to address.
A spokesperson told WSJ that the Forum is now looking for a new chair and plans to complete the process by January 2027.
Several top executives are leaving, including Chief Legal Officer Nicola Port, tech and digital services head Malte Godbersen, and Managing Director Olivier Schwab, the founder&#8217;s son. His daughter Nicole Schwab also left the Forum in December.
The WSJ report added, citing a staff memo, that two senior managing directors—Saadia Zahidi and Jeremy Jurgens—had some of their duties reduced as part of a recent reorganization.
&#8220;Over these past months, we have taken time—time to pause, to listen, and to reflect,&#8221; Brende said in the memo. &#8220;This period of reflection has been grounded in a desire not just to do things differently, but to do them better.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44897214/nvidia-discusses-ai-powering-future-with-japan-amid-rising-energy-demands" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Jensen Huang Meets Japanese PM To Discuss AI&#8217;s Growing Energy Needs</a></li>
</ul>
Photo by Boris-B via Shutterstock

Government

World Economic Forum Chair Klaus Schwab Resigns After 55 Years, Interim Successor Takes Over

Wolfe Research analyst Peter Supino upgrades Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) from Peer Perform to Outperform and announces $112 price target.

Wolfe Research Upgrades Walt Disney to Outperform, Announces $112 Price Target

Scotiabank analyst Brandon Bingham maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Sector Perform and raises the price target from $25 to $26.

Scotiabank Maintains Sector Perform on Kinder Morgan, Raises Price Target to $26

Analysts highlight advertising revenue growth and future catalysts for Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) after the company beat first-quarter revenue and <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">earnings per share estimates</a>.
<h2 class="wp-block-heading">The Netflix Analysts</h2>
<ul>
<li>Macquarie analyst Ross Compton maintained an Outperform rating on Netflix and raised the price target from $1,150 to $1,200.</li>
<li>JPMorgan analyst Doug Anmuth reiterated an Overweight rating and raised the price target from $1,025 to $1,150.</li>
<li>KeyBanc analyst Justin Patterson maintained an Overweight rating and raised the price target from $1,000 to $1,070.</li>
<li>Benchmark analyst Matthew Harrigan maintained a Hold rating with no price target.</li>
<li>Needham analyst Laura Martain maintained a Buy rating with a $1,126 price target.</li>
<li>Wedbush analyst Alician Reese reiterated an Outperform rating and raised the price target from $1,150 to $1,200.</li>
</ul>
Macquarie: Advertising monetization could give Netflix a competitive advantage, Compton said in a new investor note.
"Mgmt confirmed they are not seeing a slowdown or pullback in add spend given recent macro uncertainty," he said.
Future catalysts for Netflix include further price increases and the company's upcoming content slate, Compton added. "Its ad-tier represents a broadened and deepened that comfortably paves multi-year double-digit top line growth."
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/03/44574912/elon-musk-attacks-netflix-hit-series-shares-anti-white-propaganda-allegation-heres-how-the-shows-writer-claps-back">Elon Musk Attacks Netflix Hit Series, Shares &#8216;Anti-White Propaganda&#8217; Allegation: Here&#8217;s How The Show&#8217;s Writer Claps Back</a>
JPMorgan: The streaming company is "playing offense," while its stock remains defensive, Anmuth said in a new investor note.
The analyst said Netflix's first-quarter financial results and outlook were "solid" and point to confidence in the 2025 full-year results.
Anmuth said that double-digit revenue growth supports Netflix&#8217;s bull thesis. He also cited operating margin expansion, improving profit and cash content discipline, a strong leadership position, and the company's potential to become a global TV company with international expansion.
"We believe NFLX is a key beneficiary and driver of the ongoing disruption of linear TV, with Netflix's content performing well globally and driving a virtuous circle of strong subscriber growth, more revenue, and growing profit," Anmuth said.
KeyBanc: The streaming giant highlighted its minimal impact from tariffs and macroeconomic concerns along with strength for its advertising business, Patterson said in a new investor note.
"Netflix's 1Q results reinforced that the Company is relatively insulated from the macro, has 2H catalysts (Stranger Things, Wednesday), and a margin cushion," Patterson said.
The analyst said ad personalization is still in the early innings and Netflix should benefit from its ad-tech platform going forward.
"We believe Netflix is poised for more balanced growth between subscribers and monetization over the MT."
Benchmark: Harrigan said in a new investor note that Netflix shares could be fairly valued despite the bulls&#8217; proposition that they are a safe-haven stock.
The analyst said the stock may provide a buffer against Trump tariffs and global recession, but has limited upside to the stock price.
"Given management's decision not to continue reporting quarterly member tallies we have now pivoted our primary valuation sensitivity to realized 2030 revenue and operating margins," Harrigan said.
Harrigan said Netflix would be "considerably overvalued" if traded as a media company.
Needham: The streaming giant faced more questions about advertising given it no longer breaks out subscriber figures or paid member growth, Martin said in a new analyst note.
"NFLX stated that it has seen no meaningful changes in retention, churn, or plan mix owing to tariffs or a slowing economy," Martin said.
The analyst said Netflix sees its ad-tier ($7.99/month) as a defensive move to keep churn low. The company said it expects advertising revenue to double in 2025.
Martin said the things to like the most about Netflix are global scale, price increases, bundling with other services and advertising revenue growth accelerating. Wedbush: With a "virtually insurmountable lead in the streaming wars," Netflix gets a price target increase from Reese in a new investor note.
The analyst said Netflix's first-quarter results likely came with higher subscriber additions and revenue per member, despite the company no longer sharing these figures.
"Even with higher pricing, offering its members a vast library of original and licensed content and the option to trade down to less expensive tiers has significantly limited churn," Reese said.
Reese said Netflix is also positioned to boost its ad-tier with live events and improved advertising solutions.
"While massive subscribers growth was the primary driver in 2024, we expect price increases to drive revenue growth in 2025, and the ad tier to drive revenue higher in 2026."
Price Action: Netflix stock is up 2.6% to $998.74 on Monday versus a 52-week trading range of $542.01 to $1,064.50. Netflix stock is up 12.6% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports/25/03/44291855/netflix-stock-to-kick-and-punch-higher-streamer-could-add-ufc-rights-to-its-growing-sports-library">Netflix Stock To Kick And Punch Higher? Streamer Could Add UFC Rights To Its Growing Sports Library</a></li>
</ul>
Image: Shutterstock

Entertainment

Reiteration

NFLX

Netflix 'Playing Offense' While Stock Plays Defense: 6 Analysts On Q1 Results, Advertising Growth Ahead

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) briefly tapped $88,000 in Monday trading, eliciting bullish calls from traders that cite a strong high-timeframe structure and <a href="https://www.benzinga.com/money/bitcoin-price-prediction">improving macro backdrop</a>.
What Happened: Crypto trader Astronomer <a href="https://x.com/astronomer_zero/status/1914332318841622646">flagged</a> the move as significant, calling $88,000 a key target from his original bottom thesis. 
Despite hitting this milestone, he has not opened short positions, citing a lack of meaningful sell walls, ongoing order book strength and continued whale-led accumulation.
Astronomer says the only short trigger would be a sweep of $88,700, signs of whale distribution and local top signals. 
He expects any potential reversal to appear by Tuesday or Wednesday, ideally confirmed with a bearish weekly close. Until then, he's riding spot longs and is open to reloading at midrange levels.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44894280/how-traders-can-make-money-when-bitcoin-trades-sideways-10x-research">How Traders Can Make Money When Bitcoin Trades Sideways: 10x Research</a>
Why It Matters: Another trader, Nachi, <a href="https://x.com/alphawifhat/status/1914243855488360718?s=46">shared</a> that he entered BTC at $80,000 and Solana at $110, following President Trump's recent announcement of a 90-day pause on tariffs, a move he interprets as a sign that peak hawkishness may have passed.
Nachi maintains a bullish thesis, backed by the BTC/gold ratio holding strong, high-timeframe bullish structure, early signs of Bitcoin decoupling from equities, a weaker dollar amid fragile macro conditions and renewed central bank liquidity injection. 
What's Next: Nachi's base case is that Summer 2025 (April–August) could be the most bullish stretch, marking a pivot from maximum bearishness to easing macro trends. 
Rate cuts, stimulus measures, and softer trade policy could further fuel upside.
He notes one caveat: if Trump reverses his tariff stance by June, the bullish macro narrative could stall, but until then, the trend looks up.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44896411/bitcoin-catapults-to-87000-what-is-going-on">Bitcoin Catapults To $87,000: What Is Going On?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Briefly Hits $88,000: What's Next?

Scotiabank analyst Nat Schindler maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Sector Perform and lowers the price target from $627 to $525.

Scotiabank Maintains Sector Perform on Meta Platforms, Lowers Price Target to $525

Evercore ISI Group analyst Samir Khanal maintains Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) with a Outperform and lowers the price target from $43 to $40.

REXR

Evercore ISI Group Maintains Outperform on Rexford Industrial Realty, Lowers Price Target to $40

<a href="https://www.biopharmadive.com/news/novo-oral-semaglutide-fda-approval-application-obesity/745882/">https://www.biopharmadive.com/news/novo-oral-semaglutide-fda-approval-application-obesity/745882/</a>

Novo Announces It Has Submitted Its Obesity Pill For FDA Approval

Evercore ISI Group analyst Mark Mahaney maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $1100 to $1150.

Evercore ISI Group Maintains Outperform on Netflix, Raises Price Target to $1150

Scotiabank analyst Nat Schindler maintains Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) with a Sector Outperform and lowers the price target from $232 to $200.

GOOG

GOOGL

Scotiabank Maintains Sector Outperform on Alphabet, Lowers Price Target to $200

<a href="https://x.com/cgasparino/status/1914369956357267870?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/cgasparino/status/1914369956357267870?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

TSLA

Charles Gasparino Posts On X "Breaking: Tesla investors expecting guidance during Tuesday's earnings call from @elonmusk on his future involvement in DOGE...."

Scotiabank analyst Nat Schindler maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Sector Outperform and lowers the price target from $306 to $250.

AMZN

Scotiabank Maintains Sector Outperform on Amazon.com, Lowers Price Target to $250

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Buy and maintains $70 price target.

QURE

HC Wainwright & Co. Reiterates Buy on uniQure, Maintains $70 Price Target

Financing

Press Releases

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Offerings

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Earnings

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

PSTV

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Alzamend Neuro

180 Life Sciences

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Galecto

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Organovo Holdings

Palisade Bio

Sunshine Biopharma

SILO Pharma

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Spruce Biosciences

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Theriva Biologics

Longevity Health Holdings, Inc. - Common Stock

Comments

Plus Therapeutics

Notizie

Ultime notizie per Plus Therapeutics (NASDAQ:PSTV) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO